<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

UM-UC-14

Description

UM-UC-14 (Bladder Cancer CDX Model) 

The UM-UC-14 line was derived from a human urothelial carcinoma of the bladder. It represents advanced bladder cancer biology. UM-UC-14 is widely used in drug testing and biomarker development. Its reproducibility ensures reliability in bladder cancer pipelines. 

Key Features: 

  • Derived from human urothelial carcinoma. 
  • Represents advanced bladder cancer. 
  • Epithelial morphology. 
  • Tumorigenic in xenografts. 

Applications: 
UM-UC-14 supports therapeutic discovery in bladder cancer. Researchers apply it in biomarker validation and drug resistance studies. It is used to test cytotoxic and targeted therapies in urothelial carcinoma. Its consistent growth makes it reliable for translational research.

Details
Tumor Type
Kidney
Tumor Subtype
Transitional Cell Carcinoma
Organism
Human
Mouse Sex
Female
Mouse Strain
NOG
Mutated Genes
FGFR3
Mutation: p.S249C
Effect: Missense Variant
Impact: Likely Pathogenic & Pathogenic
*Data provided by DepMap
PIK3CA
Mutation: p.E418K
Effect: Missense Variant, Splice Region Variant
Impact: Likely Pathogenic & Pathogenic & Uncertain Significance
*Data provided by DepMap
TP53
Mutation: p.R280T
Effect: Missense Variant
Impact: Likely Pathogenic & Pathogenic
*Data provided by DepMap
Expression Data (provided by DepMap)
Growth Curve
View on Lumin